Maze Therapeutics Inc. is a clinical-stage biopharmaceutical company developing small molecule precision medicines for renal, cardiovascular, related metabolic diseases, and obesity. The company harnesses human genetics through its Compass platform to identify genetic variants in diseases and link them to biological pathways driving conditions in specific patient populations, a process called variant functionalization. Its lead program, MZE829, is an oral small molecule inhibitor of apolipoprotein L1 (APOL1) in phase II clinical trials for APOL1 kidney disease. MZE782, another oral small molecule inhibitor targeting the solute transporter SLC6A19, is in phase I clinical trials for chronic kidney disease and phenylketonuria. Maze Therapeutics Inc. also advances MZE001 for Pompe disease. Focused on novel precision medicine approaches, it addresses unmet needs in kidney and metabolic disorders. Founded in 2017 and headquartered in South San Francisco, California, Maze Therapeutics Inc. plays a key role in advancing genetically informed therapies in the biopharmaceutical sector.